News

The trial is evaluating the use of Pexa-Vec to treat HCC patients who have failed locoregional therapies and are eligible for treatment with sorafenib (Nexavar), the only approved

UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness was

cCK18 is a mechanism-specific biomarker of caspase-driven cell death. Multiple additional liver disease biomarkers achieved statistically significant reductions vs. placebo in the overall patient population after three months

MannKind is reviewing its strategic options for Afrezza as a result of the termination of its license and collaboration agreement. The termination will take effect no later than

The study’s data monitoring committee (DMC) recommended for termination of the trial early because of lack of efficacy. Gilead is however continuing the phase 2 trials of the

HD affects muscle coordination and leads to deterioration of mental abilities and physical control. IONIS-HTT Rx, which is currently in phase 1/2a study, is an antisense drug designed

This program is evaluating vadadustat (formerly AKB-6548) in non-dialysis patients with anemia related to chronic kidney disease (NDD-CKD). In addition, the U.S. Food and Drug Administration (FDA) recently

Furthermore, high diversity among CTCs was not associated with resistance to taxane-based chemotherapy. This suggests that patients likely to fail anti-androgen therapies but potentially benefit from chemotherapy can

Matinas BioPharma president and CEO Roelof Rongen said: "In preclinical studies, MAT2501 was shown to have oral bioavailability and provide targeted delivery of the powerful antibiotic, amikacin, directly